Title | APRISO | Mesalamine Treatment for Ulcerative Colitis: UC Remission Maintenance in ***s |
Description | Discover APRISO, a once-daily mesalamine ulcerative colitis treatment indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older. |
Keywords | apriso, mesalamine, ulcerative colitis, ulcerative colitis medication, ulcerative colitis remission, uc remission, ulcerative colitis remission maintenance, uc remission maintenance |
lialda.com |
delzicol.com |
salix.com |
pentasaus.com |
canasa.com |
anime44.com |
seriesblanco.org |
capmng.com |
koa.guru |
bctelco.com |
maytte.com |
harotube.com |
jiffynotes.com |
indiarace.com |
mindyoga4u.com |
Aprisorx.com was created 15 years ago. According to Alexa, it has a global traffic rank of #3,836,882 globally. Aprisorx.com receives approximately 5,508 unique visitors per month. Web server is located in United States and has an IP address 107.154.108.80.
Creation date | 2010-01-19 |
Expiration date | 2022-01-19 |
Registrar | MarkMonitor, Inc. |
Name servers |
|
IP address | 107.154.108.80 |
Server located | United States |
Host name | 107.154.108.80.ip.incapdns.net |
Global Rank | 3,836,882 |
Delta (90 Days) | 789,293 |
Most Popular In Country | n/a |
Country Rank | n/a |
Host | Type | TTL | Data |
---|---|---|---|
aprisorx.com | A | 7199 |
ip: 107.154.108.80 |
aprisorx.com | A | 7199 |
ip: 107.154.110.80 |
aprisorx.com | NS | 86400 |
target: ns3.markmonitor.com |
aprisorx.com | NS | 86400 |
target: ns4.markmonitor.com |
aprisorx.com | NS | 86400 |
target: ns7.markmonitor.com |
aprisorx.com | NS | 86400 |
target: ns2.markmonitor.com |
aprisorx.com | NS | 86400 |
target: ns1.markmonitor.com |
aprisorx.com | NS | 86400 |
target: ns5.markmonitor.com |
aprisorx.com | NS | 86400 |
target: ns6.markmonitor.com |
aprisorx.com | SOA | 86400 |
mname: ns1.markmonitor.com rname: hostmaster.markmonitor.com serial: 2019043003 refresh: 86400 retry: 3600 expire: 2592000 minimum-ttl: 172800 |
aprisorx.com | TXT | 86400 |
txt: globalsign-domain-verification=H27Sf4xWzLLD5u9KfdGXV-Nq_dIsvnHXJpcUHLU6La |
Cache-Control: public, no-cache="Set-Cookie" Content-Type: text/html; charset=utf-8 Vary: Accept-Encoding Set-Cookie: dnn_IsMobile=False; path=/; HttpOnly Set-Cookie: language=en-US; path=/; HttpOnly Set-Cookie: .ASPXANONYMOUS=-X_fiflnN178I-iHJXWqMdDtzT-S9qHcq1hG1-M2tbgDIkcULzokXHRmnWzmx_UaUB1ccVEhPZ5ivv0CqkwXrEo6-3x0OQNQrozEavgwNTDaDoIG0; expires=Mon, 25-Jan-2021 00:19:33 GMT; path=/; HttpOnly Set-Cookie: Analytics_VisitorId=b31becfb-2226-4938-9b42-a0521899798b; expires=Wed, 16-Dec-2020 13:39:33 GMT; path=/; HttpOnly Set-Cookie: Analytics=SessionId=39f74973-868f-46d7-bf29-e2da9ffee7b5&TabId=13051&ContentItemId=-1; expires=Mon, 16-Nov-2020 14:39:33 GMT; path=/; HttpOnly Set-Cookie: dnn_IsMobile=False; path=/; HttpOnly Set-Cookie: language=en-US; path=/; HttpOnly Set-Cookie: .ASPXANONYMOUS=-X_fiflnN178I-iHJXWqMdDtzT-S9qHcq1hG1-M2tbgDIkcULzokXHRmnWzmx_UaUB1ccVEhPZ5ivv0CqkwXrEo6-3x0OQNQrozEavgwNTDaDoIG0; expires=Mon, 25-Jan-2021 00:19:33 GMT; path=/; HttpOnly Set-Cookie: Analytics_VisitorId=b31becfb-2226-4938-9b42-a0521899798b; expires=Wed, 16-Dec-2020 13:39:33 GMT; path=/; HttpOnly Set-Cookie: Analytics=SessionId=39f74973-868f-46d7-bf29-e2da9ffee7b5&TabId=13051&ContentItemId=-1; expires=Mon, 16-Nov-2020 14:39:33 GMT; path=/; HttpOnly Set-Cookie: __RequestVerificationToken=VkNTXpvL4gbFxTvQH4aVmd7qawjitPW-5Q2KMZmIe1QJixNQwgWOtegsWke9NVNY7Q_HSA2; path=/; HttpOnly Set-Cookie: visid_incap_820241=G9w6plqaSeKzHBA5tZSe1RSBsl8AAAAAQUIPAAAAAACZ5aQNXEptp2ShNpdGPvju; expires=Tue, 16 Nov 2021 12:10:17 GMT; HttpOnly; path=/; Domain=.aprisorx.com Set-Cookie: nlbi_820241=L0FkUiBzGURP1RKiuJfobAAAAACaPHADYYtWPau8MmRoZF58; path=/; Domain=.aprisorx.com Set-Cookie: incap_ses_1251_820241=4lCyIZBE024FtBkhOnJcERWBsl8AAAAALpu1SoXJloK0H0kRoW3HPw==; path=/; Domain=.aprisorx.com Set-Cookie: ___utmvmFVBumLBX=KztZUXuutOo; path=/; Max-Age=900 Set-Cookie: ___utmvaFVBumLBX=wVtjhVc; path=/; Max-Age=900 Set-Cookie: ___utmvbFVBumLBX=AZl X-UA-Compatible: IE=edge X-XSS-Protection: 1; mode=block X-Frame-Options: SAMEORIGIN Date: Mon, 16 Nov 2020 13:39:32 GMT XvdOVala: btI; path=/; Max-Age=900 X-CDN: Incapsula Transfer-Encoding: chunked X-Iinfo: 8-87188101-87188107 NNNN CT(18 56 0) RT(1605533972887 32) q(0 0 0 0) r(1 1) U12 x-encoded-content-encoding: gzip |
Domain Name: aprisorx.com Registry Domain ID: 1582376191_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2019-12-19T02:34:03-0800 Creation Date: 2010-01-19T06:39:28-0800 Registrar Registration Expiration Date: 2022-01-19T00:00:00-0800 Registrar: MarkMonitor, Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895770 Domain Status: clientUpdateProhibited (https://www.icann.org/epp#clientUpdateProhibited) Domain Status: clientTransferProhibited (https://www.icann.org/epp#clientTransferProhibited) Domain Status: clientDeleteProhibited (https://www.icann.org/epp#clientDeleteProhibited) Registrant Organization: Valeant Pharmaceuticals International Registrant State/Province: NJ Registrant Country: US Registrant Email: Select Request Email Form at https://domains.markmonitor.com/whois/aprisorx.com Admin Organization: Valeant Pharmaceuticals International Admin State/Province: NJ Admin Country: US Admin Email: Select Request Email Form at https://domains.markmonitor.com/whois/aprisorx.com Tech Organization: Valeant Pharmaceuticals International Tech State/Province: NJ Tech Country: US Tech Email: Select Request Email Form at https://domains.markmonitor.com/whois/aprisorx.com Name Server: ns7.markmonitor.com Name Server: ns4.markmonitor.com Name Server: ns5.markmonitor.com Name Server: ns2.markmonitor.com Name Server: ns3.markmonitor.com Name Server: ns6.markmonitor.com Name Server: ns1.markmonitor.com DNSSEC: unsigned URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/ |